Perspective Therapeutics (CATX) Accumulated Depreciation (2011 - 2026)

Perspective Therapeutics has disclosed Accumulated Depreciation across 14 years of filings, most recently posting $8.5 million for Q2 2026.

• In Q2 2026, Accumulated Depreciation rose 91.5% year-over-year to $8.5 million; the TTM figure through Jun 2026 stood at $8.5 million (up 91.5% YoY), while the FY2025 annual figure was $6.2 million, up 109.59% from the prior year.
• Accumulated Depreciation came in at $8.5 million for Q2 2026 at Perspective Therapeutics, up from $7.3 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $8.5 million in Q2 2026 to a low of $15000.0 in Q4 2022.
• Average Accumulated Depreciation over 5 years is $5.0 million, with a median of $5.7 million recorded in 2025.
• Year-over-year, Accumulated Depreciation sank 99.8% in 2022 and soared 4360.0% in 2023.
• Over 5 years, Accumulated Depreciation stood at $15000.0 in 2022, then soared by 4360.0% to $669000.0 in 2023, then soared by 342.45% to $3.0 million in 2024, then surged by 109.59% to $6.2 million in 2025, then soared by 36.49% to $8.5 million in 2026.
• Per Business Quant data, the three most recent Accumulated Depreciation figures were $8.5 million in Q2 2026, $7.3 million in Q1 2026, and $6.2 million in Q4 2025.